This list is an analysis based on recent market events. It's not an investment recommendation.
MedPacto, Inc. is a South Korean biopharmaceutical company specializing in the research and development of novel therapeutic solutions for oncology and autoimmune conditions. The firm's pipeline includes several key drug candidates: ME-1601mAb, an investigational treatment designed to target BSP1 for various cancers; MS-1601A, which addresses both cancerous and autoimmune diseases by targeting TRG1; and vactosertib, a therapeutic candidate aimed at solid tumors. MedPacto is headquartered in Seoul, South Korea.
FAQs
What is MedPacto stock price today?▼
The current price of 235980.KQ is ₩3,350 KRW — it has decreased by -6.03% in the past 24 hours. Watch MedPacto stock price performance more closely on the chart.
What is MedPacto stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange MedPacto stocks are traded under the ticker 235980.KQ.
Is MedPacto stock price growing?▼
235980.KQ stock has risen by +11.11% compared to the previous week, the month change is a +12.79% rise, over the last year MedPacto has showed a -27.96% decrease.
What is MedPacto market cap?▼
Today MedPacto has the market capitalization of 114.82B
What is MedPacto revenue for the last year?▼
MedPacto revenue for the last year amounts to 3.9B KRW.
What is MedPacto net income for the last year?▼
235980.KQ net income for the last year is -12.81B KRW.
How many employees does MedPacto have?▼
As of November 3, 2026, the company has 54 employees.
In which sector is MedPacto located?▼
MedPacto operates in the Health & Wellness sector.
When did MedPacto complete a stock split?▼
The last stock split for MedPacto was on May 13, 2020 with a ratio of 1:1.
Where is MedPacto headquartered?▼
MedPacto is headquartered in Seoul, South Korea.